Syngene appoints Siddharth Mittal as Managing Director & CEO
Syngene International has appointed Siddharth Mittal as Managing Director and Chief Executive Officer, effective July 1, 2026, succeeding Peter Bains who resigned on June 30, 2026. Mittal, formerly the MD & CEO of Biocon Limited, brings nearly three decades of experience to drive commercial edge and operational excellence.

*this image is generated using AI for illustrative purposes only.
Syngene International has appointed Siddharth Mittal as its Managing Director and Chief Executive Officer, effective July 1, 2026. The leadership change marks a strategic transition for the global contract research, development, and manufacturing organization (CRDMO) as it aims to strengthen its commercial edge and operational excellence. Mittal succeeds Peter Bains, who completed his tenure as Managing Director & CEO on June 30, 2026.
Mittal brings nearly three decades of business leadership experience to the role. He joins Syngene International from Biocon Limited, where he most recently served as the Managing Director and Chief Executive Officer. During his thirteen-year tenure at Biocon, he held the position of Chief Financial Officer before being appointed to the top leadership role. His tenure included securing key regulatory approvals and commercializing the GLP-1 portfolio across major international markets.
Kiran Mazumdar-Shaw, Executive Chairperson of Syngene International, expressed confidence in the new appointment. She stated that Syngene is at an inflection point and that Mittal's leadership, commercial acumen, and execution focus will help the company unlock its full potential. She highlighted his ability to lead businesses through periods of change and deliver sustainable growth.
Commenting on his new role, Siddharth Mittal said his immediate priority is to sharpen the company's commercial edge and strengthen delivery excellence. He emphasized combining scientific strengths with a focus on customer fulfilment and cost-competitiveness to restore growth momentum. Mittal aims to reinforce Syngene's standing as a global leader in CRDMO services.
Key Leadership Transition
The following table summarizes the key details of the leadership change at Syngene International:
| Aspect: | Details |
|---|---|
| New Role: | Managing Director & CEO |
| Effective Date: | July 1, 2026 |
| Predecessor: | Peter Bains |
| Previous Company: | Biocon Limited |
| Experience: | Nearly three decades |
Historical Stock Returns for Syngene International
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.02% | +0.80% | -0.19% | -33.17% | -31.12% | -25.25% |
How will Mittal's prior experience with the GLP-1 portfolio influence Syngene's strategy in the high-growth biologics and peptide markets?
What specific operational changes can be expected under Mittal's leadership to improve cost-competitiveness and delivery excellence?
Will the leadership transition trigger a shift in Syngene's client acquisition strategy towards new geographies or therapeutic areas?































